A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 1 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 10, 2024 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-0791800 (TTI-621); Drug: PF-07901800 (TTI-621) plus Rituximab; Drug: PF-07901800 (TTI-621) plus Nivolumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- MAJOR ELIGIBILITY CRITERIA: Phase 1a Escalation
- Histologically documented, measurable, advanced lymphomas, transfusion-independence Phase 1b Expansion (Part 2 and 3)
- Advanced malignancy: IBCL, ABCL, cHL, AML, ALL, MDS, MPN, SCLC, PTCL and CTCL; measurable disease who have relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1 prior systemic attempt for PTCL). For CTCL, extracorporeal photochemotherapy (ECP) considered a systemic therapy. Local radiation and topical agents are not systemic therapies. Phase 1b dose optimization (Part 4)
- Histologically confirmed diagnosis of CTCL (both Mycosis Fungoides and Sezary Syndrome): Failed at least 2 prior systemic therapies for CTCL (Systemic therapy does not include local radiation therapy or topical agents); History of histologically documented diagnosis of CTCL stage IB to IVB (all subjects):
- Advanced measurable malignancy with previously progressed on, or currently progressing on standard anticancer therapy or for whom no other approved conventional therapy exists
- Eastern Cooperative Oncology Group (ECOG) 0-2
- Adequate hematologic, hepatic, renal, and coagulation function; fresh or archived tumor tissue available for immunohistochemistry
- Recovery from prior treatments and/or surgeries; no history of hemolytic anemia or bleeding diathesis.
- AML M3 (French American British, FAB, classification) (i.e., acute promyelocytic leukemia \[APL\]) excluded
- Known current central nervous system disease involvement or untreated brain metastases
- Allogeneic transplant within 30 days prior to the planned start of treatment or subjects with active graft-vs-host disease with the exception of Grade 1 skin involvement
- History of hemolytic anemia or bleeding diathesis
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- City of Hope National Medical CenterDuarte, California
- City of HopeDuarte, California
- Freidenrich Center for Translational Research (CTRU)Palo Alto, California
- Stanford Cancer InstitutePalo Alto, California
- Colorado Blood Cancer InstituteDenver, Colorado
- Presbyterian/St.Luke's Medical CenterDenver, Colorado
- Mayo Clinic JacksonvilleJacksonville, Florida
- Mayo ClinicJacksonville, Florida
- Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley CampusTampa, Florida
- Moffitt Cancer CenterTampa, Florida
- Covance BiorepositoryGreenfield, Indiana
- Mayo ClinicRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 10, 2024. Always confirm current availability with the study team.